Fig. 2: Summary of biomarker associations with efficacy. | Nature Communications

Fig. 2: Summary of biomarker associations with efficacy.

From: Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer

Fig. 2

Biomarker associations are shown with A ORR per INV, B PFS per INV, and C OS. Data are presented as odds ratios ± 95% CIs (A) or hazard ratios ± 95% CIs (B, C). Data for GES and CD3 IHC are from all RNA-seq–evaluable patients (n = 57) and all CD3 IHC-evaluable patients (n = 59), respectively; data for TMB, degree of MSI, and TIB, are from all WES-evaluable patients (n = 59). CD3 cluster of differentiation 3, CI confidence interval, DC dendritic cell, GES gene expression signature, IHC immunohistochemistry, IPI ipilimumab, MSI microsatellite instability, NIVO nivolumab, NK natural killer cell, TCD8 CD8+ T cell, TIB tumor indel burden, TLS tertiary lymphoid structure, TMB tumor mutational burden, Treg regulatory T cell. Source Data are available.

Back to article page